pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Amtagvi
drug · cell
save

lifileucel

Phase 3updated 3mo ago
by $IOVA IOVANCE BIOTHERAPEUTICS, INC.🔗 ChEMBL
Phase 3
community read0 votes

Cell drug with a maximum clinical stage of Approval (across all indications), with an approval for cutaneous melanoma and 11 investigational indications.

indications

indications
NSCLC

all catalysts(0)

nothing on the calendar yet

Trials studying lifileucel

  • phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcomanot yet recruitingn=80
  • phase2Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanomacompletedn=11
  • phase3SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanomarecruitingn=360
  • phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanomaactive not recruitingn=100
  • —Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Releaseavailable
  • phase3Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.recruitingn=670
  • phase2Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanomacompletedn=220
  • phase1Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patientsactive not recruitingn=2
more trials →

News(1)

  • FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
    The FDA's rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s Duchenne muscular dystrophy cell therapy.
    biospace · 14d ago
brand
Amtagvi
trade names
Amtagvi
generic
lifileucel
indication
Metastatic Melanoma
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 40m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?